---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060256"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:09:36.411107+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Q1 net revenue drops 25% YoY to $2.0M; OnTarget top line due Oct 2023

## Summary
- Net revenue $2.0M, down 25% YoY from $2.6M and 40% QoQ from $3.3M.
- Net loss to common stockholders improved to $12.2M from $18.0M YoY; EPS –$2.39 vs –$23.10.
- PIPE closed raising ~$1.86M; no equity issuance before Oct 22, 2023 under agreement.
- Phase 3 OnTarget trial enrollment completed; top line results expected October 2023.
- IND submission for crofelemer in MVID planned Q2 2023.

## SEC filing metadata
- accession: 0001104659-23-060256
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/0001104659-23-060256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/tm2315707d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060256
- JSON: https://secwatch.observer/filing/0001104659-23-060256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060256.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported first quarter 2023 results: revenue $2.00 million.
  - Period: first quarter 2023
  - Revenue: $2.00 million
  - Result: reported results
  source text: The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $2.00 million in the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/0001104659-23-060256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.